OPTIMIZATION OF TREATMENT OUTCOMES FOR TRAUMATIC CATARACT IN CHILDREN USING RECOMBINANT PROUROKINASE

Abstract

Traumatic cataract is a major cause of visual disability in children, often leading to complications that challenge surgical treatment and recovery. To assess the efficacy of recombinant prourokinase ("Hemaza") in reducing postoperative complications and improving visual outcomes in children. Sixty children (60 eyes) with traumatic cataracts were treated using standard techniques (n=28) or with intraoperative "Hemaza" (n=32). Outcomes were evaluated by visual acuity, complications, and IOL stability. The "Hemaza" group showed no complications (e.g., exudative reactions, hyphema) and improved visual acuity (0.5–1.0 at discharge, 0.6–1.0 after 2–6 months). The standard group had higher complication rates and less visual improvement. "Hemaza" effectively prevents complications and enhances outcomes in pediatric traumatic cataract surgery, supporting safer, faster recovery.